TG Therapeutics reported strong financial performance for 2024, driven by the success of BRIUMVI, a treatment for relapsing multiple sclerosis. The company achieved $103.6 million in U.S. net revenue for BRIUMVI in the fourth quarter and $310 million for the full year, reflecting significant growth. It set a 2025 revenue target of approximately $540 million, with $525 million expected from BRIUMVI sales in the U.S.

Key developments include the expansion of BRIUMVI’s patent protection through 2042, its commercial launch in Europe, and promising five-year data showing sustained efficacy and safety. Clinical trials for a subcutaneous version of BRIUMVI and its application for autoimmune diseases are underway. The company also entered a licensing agreement for an allogeneic CD19 CAR T therapy.

Financially, TG Therapeutics reported net product revenue of $313.7 million for 2024, a significant increase from $92 million in 2023. Net income was $23.3 million for the year, compared to $12.7 million in 2023. Research and development expenses rose to $94.3 million due to new trials and licensing costs. The company ended 2024 with $311 million in cash and investment securities, expecting this to support ongoing operations.

A conference call was scheduled for March 3, 2025, to discuss these results. The company remains focused on expanding BRIUMVI’s reach, developing new treatment options, and achieving key clinical milestones in 2025.